Cas:6713-41-3 endo-bicyclo<2.2.1>heptane-2,3-dicarboximide manufacturer & supplier

We serve Chemical Name:endo-bicyclo<2.2.1>heptane-2,3-dicarboximide CAS:6713-41-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

endo-bicyclo<2.2.1>heptane-2,3-dicarboximide

Chemical Name:endo-bicyclo<2.2.1>heptane-2,3-dicarboximide
CAS.NO:6713-41-3
Synonyms:(1R,7S)-4-Azatricyclo[5.2.1.0]decane-3,5-dione;4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-, (4R,7S)-
Molecular Formula:C9H11NO2
Molecular Weight:165.189
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:355.3±11.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.555
PSA:49.66000
Exact Mass:165.078979
LogP:0.22

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (1R,7S)-4-Azatricyclo[5.2.1.0]decane-3,5-dione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-, (4R,7S)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(1R,7S)-4-Azatricyclo[5.2.1.0]decane-3,5-dione Use and application,4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-, (4R,7S)- technical grade,usp/ep/jp grade.


Related News: Despite the $13 million first-quarter hit from the rate cut, iRhythm grew revenue year over year by 17% to $74.3 million in the quarter. iRhythm’s net losses for the quarter totaled $27.8 million, compared to a net loss of $9.1 million in the first quarter of 2020. trimethyl-[(4-nitrophenyl)methyl]silane manufacturers The booster campaign, with shots administered by health maintenance organisations, will effectively turn Israel into a testing ground for a third dose before approval by the U.S. Food and Drug Administration (FDA). 5-(1-benzyl-1H-pyrrol-2-yl)-4,5-dihydrothieno[2,3-c]pyridin-7-amine suppliers For these reasons, many pharmaceutical companies are choosing to evaluate biocatalytic processes during early-stage drug development to avoid missing opportunities for capitalizing on these gains. (5-chloro-4-fluoro-2-{(E)-3-[(R)-4-(4-fluoro-benzyl)-2-ethyl-piperazin-1-yl]-3-oxo-propenyl}-phenyl)-urea vendor & factory.